Translational Research E- Conference
ACUTE LYMPHOBLASTIC LEUKAEMIA

May 7-9, 2021

Chairpersons: Jan Cools (Leuven), Hervé Dombret (Paris), Adele Fielding (London), Mark Litzow (Rochester)

Friday, May 7th, 2021

13:50-14:00 Welcome: The 4 Chairpersons

SESSION I – BIOLOGY OF B-CELL PRECURSOR ALL
Chairs: Jan Cools (Leuven) & Adolfo Ferrando (New York)

14:00-14:05 Introduction Jan Cools & Adolfo Ferrando
14:05-14:25 Keynote: HOX Gene Deregulation in ALL Scott Armstrong (Boston)
14:25-14:40 Transcriptional Landscape of B-cell Precursor ALL Henrik Lilljbjörn (Lund)
14:40-14:55 Myeloid Switch of B-cell Precursor ALL Subtypes Ester Mejstrikova (Prague)
14:55-15:10 Targeting Novel B-cell progenitor ALL Subtypes Charles Mullighan (Memphis)

BRIEF ORAL COMMUNICATION:

15:10-15:20 Mechanistic Basis for Targeting BCL6 in RAS-Driven B-Cell Acute Lymphoblastic Leukemia Lai Chan (New Haven)

15:20-15:50 Panel discussion

SESSION II – BIOLOGY OF T-CELL ALL
Chairs: Charles Mullighan (Memphis) & Scott Armstrong (Boston)

15:50-15:55 Introduction Charles Mullighan & Scott Armstrong
15:55-16:10 Molecular Mechanisms of T-ALL Adolfo Ferrando (New York)
16:10-16:25 Aberrant Signaling in T-cell ALL Jan Cools (Leuven)
16:25-16:40 Targeting CD3 in T-ALL Jacques Ghysdael (Orsay)
LIVE Programme CEST time

**BRIEF ORAL COMMUNICATION:**

16:40-16:50  
*Tonic T-Cell Receptor Signaling Is Leukemogenic While Its Antigenic Stimulation Suppresses Leukemia Development*  
Telmo A. Catarino (Porto)

16:50-17:20  
*Panel discussion*

17:20-17:30  
*Break*

**SESSION III – MINIMAL RESIDUAL DISEASE MONITORING**  
Chairs: Sabina Chiaretti (Rome) & Selina Luger (Philadelphia)

17:30-17:35  
*Introduction*  
Sabina Chiaretti & Selina Luger

17:35-17:50  
*Euro MRD Activities*  
Beat Schäfer (Zurich)

17:50-18:05  
*Which MRD for ALL Treatment Stratification?*  
Monika Brüggemann (Kiel)

18:05-18:20  
*IG-TCR versus BCR-ABL1 MRD in Ph+ ALL*  
Jan Zuna (Prague)

**BRIEF ORAL COMMUNICATION:**

18:20-18:30  
*Knockout of HMGN1 In Vivo reduces CRLF2r down Syndrome Acute Lymphoblastic Leukaemia Burden and Increases Survival Outcomes*  
Elyse Page (Adelaide)

18:30-19:00  
*Panel discussion*

19:00  
*Mentored Poster Walk #1*  
*Poster Leaders: Richard Burt (London) & Anna Castleton (Manchester)*

---

**Saturday, May 8th, 2021**

10:30-11:30  
**2 Simultaneous Meet the Expert sessions (non clinical)**  
- *Role of HSCT in Ph+ ALL*: Oliver Ottmann & Hervé Dombret  
- *Monitoring L-asparaginase Efficacy in ALL Patients*: Mathilde Hunault & Adele Fielding

11:30-12:30  
*Mentored Poster Walk #2*  
*Poster Leaders: Bela Wrench (London) & Charles de Bock (Sydney)*

12:30-13:30  
*Lunch*

**SESSION IV – INDIVIDUALIZED MANAGEMENT OF ALL**  
Chairs: Nicola Gökbuget (Frankfurt) & Elizabeth Raetz (New York)

13:30-13:35  
*Introduction*  
Nicola Gökbuget & Elizabeth Raetz

13:35-13:50  
*Treatment Issues in Teenagers and Young Adults ALL*  
Rachael Hough (London)
LIVE Programme CEST time

13:50-14:05  Treatment Issues in Older ALL  Selina Luger (Philadelphia)
14:05-14:20  Management of Relapsed ALL  Elias Jabbour (Houston)

**BRIEF ORAL COMMUNICATION:**

14:20-14:30  \( T(1;19)(q23;p13) \) TCF3-PBX1 May Not be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated with MRD-Oriented Protocols from the Pethema Group  Jordi Ribera (Badalona)

14:30-15:00  Panel discussion

**SESSION V – NEW ADVANCES IN ALL**

Chairs: Hervé Dombret (Paris) & Shannon Maude (Philadelphia)

15:00-15:05  Introduction  Hervé Dombret & Shannon Maude
15:05-15:20  The Critical Role of Microenvironment in ALL  Adele Fielding (London)
15:20-15:35  TKI Use in Ph+/Ph-like Diseases  Stephen Hunger (Philadelphia)
15:35-15:50  New ALL Drugs  Matthew Wieduwilt (San Diego)

**BRIEF ORAL COMMUNICATIONS:**

15:50-16:00  Lysosome-Mediated Dysregulation of Lipid Metabolism Selectively Induces Autophagy-Dependent Cell Death in T-ALL  Ruth M Risueño (Barcelona)
16:00-16:10  Pharmacologic Inhibition of DYRK1A Results in Hyperphosphorylation of ERK and Consequently in Apoptosis of KMT2A-Rearranged ALL  Christian Hurtz (Philadelphia)
16:10-16:20  Oncogenic Cooperation between the TCF7-SPI1 fusion and NRAS(G12D) Requires β-Catenin Activity to Drive T-Cell Acute Lymphoblastic Leukemia.  Quentin Van Thillo (Leuven)

16:20-16:50  Panel discussion

16:50-17:00  Break

**SESSION VI – CAR T-CELLS & ALLOGENEIC HSCT**

Chairs: Adele Fielding (London) & Nicolas Boissel (Paris)

17:00-17:05  Introduction  Adele Fielding & Nicolas Boissel
17:05-17:20  Outcome of ALL Patients Treated with CAR T-cells  Shannon Maude (Philadelphia)
17:20-17:35  New CARs for B-cell Precursor ALL  Claire Roddie (London)
17:35-17:50  Post-transplant Interventions  David Marks (Bristol)
17:50-18:20  Panel discussion
SESSION VII – FRONTLINE INCORPORATION OF BiTEs and ADCs
Chairs: Mark Litzow (Rochester) & Anjali Advani (Cleveland)

18:20-18:25  Introduction  
Mark Litzow & Anjali Advani

18:25-18:45  Keynote: The MD Anderson Cancer Center Experience  
Hagop Kantarjian (Houston)

18:45-19:00  Adult ALL Trials  
Nicola Gökbuget (Frankfurt)

19:00-19:15  Childhood ALL Trials  
Lia Gore (Aurora)

19:15-19:30  Frontline Chemo-free Regimens in Ph+ ALL  
Sabina Chiaretti (Rome)

19:30-20:00  Panel discussion

Sunday, May 9th, 2021

13:00-14:00  4 Simultaneous Meet the Expert Sessions (Non- Clinical & Clinical)
- CAR T-cells : Practical Issues: Nicolas Boissel & Shannon Maude
- MRD Issues: Monika Brüggemann & Jan Zuna
- Allogenic SCT in ALL: Open issues: David Marks & Mark Litzow
- Optimal use of BiTEs: Nicola Gökbuget & Matthew Wieduwilt

SESSION VIII – T-CELL ALL and LYMPHOBLASTIC LYMPHOMA
Chairs: Anjali Advani (Cleveland) & David Marks (Bristol)

14:00-14:05  Introduction  
Anjali Advani & David Marks

14:05-14:25  Keynote: Management of T-LL Patients  
Dieter Hoelzer (Frankfurt)

14:25-14:40  Risk Factors in T-ALL  
Elizabeth Raetz (New York)

14:40-14:55  Should T-LL and T-ALLs be treated on the same protocols?  
Elisabeth Macintyre (Paris)

14:55-15:10  Novel Therapies for T-ALL/LL  
Anjali Advani (Cleveland)

BRIEF ORAL COMMUNICATION:

15:10-15:20  Pre-T Cell Receptor As a Therapeutic Target in T-Cell Acute Lymphoblastic Leukemia  
Maria L Toribio (Madrid)

15:20-15:50  Panel discussion

15:50-16:00  Break

SESSION IX – Ph AND Ph-LIKE ALL
Chairs: Oliver Ottmann (Cardiff) & Sabina Chiaretti (Rome)

16:00-16:05  Introduction  
Oliver Ottmann & Sabina Chiaretti
LIVE Programme CEST time

16:05-16:20  Which TKI-Chemo-Transplant Cocktail for Ph+ ALL?  Yves Chalandon (Geneva)

16:20-16:35  Next generation TKIs for Ph+ ALL  Nicholas Short (Houston)

16:35-16:50  Ph-like ALL Patient Management  Sarah Tasian (Philadelphia)

**BRIEF ORAL COMMUNICATION:**

16:50-17:00  IL7R Gain-of-Function Mutation Is Sufficient to Initiate B-Cell Acute Lymphoblastic Leukemia In Vivo with Features of PAX5 P80R and Ph-like ALL  Afonso R.M. Almeida (Lisboa)

17:00-17:30  Panel discussion

17:30-17:45  Closing Remarks: The 4 Chairpersons